From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

Activating mutations of the Epidermal Growth Factor Receptor (EGFRMUT) gene are found in approximately 10-12% of Caucasian patients affected by non small-cell lung cancer (NSCLC), with higher prevalence in adenocarcinoma histology, never smokers and females [1]. Exon 19 deletions and exon 21 L858R point mutation represent about 90% of these activating alterations [2]. For many years, first- (gefitinib and erlotinib) or second-generation (afatinib) EGFR-tyrosine kinase inhibitors (TKIs) have been considered the standard first-line therapy for patients with advanced EGFR-mutated NSCLC, based on the excellent outcome in comparison with standard chemotherapy [1].

Source: Lung Cancer - March 18, 2019 Category: Cancer & Oncology Authors: Paola Bordi, Marzia Del Re, Roberta Minari, Eleonora Rofi, Sebastiano Buti, Giuliana Restante, Anna Squadrilli, Stefania Crucitta, Chiara Casartelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Iacopo Petrini, Agnese Cosenza, Leonarda Ferri, Elena R Source Type: research